Another GLP-1/GIP/Glucagon Triple Agonist Has Officially Entered the Race
NBIP-1968 research snapshot: Neurocrine’s investigational triple agonist targets GIP, GLP-1 and glucagon receptors. The company has announced a Phase 1 study, but its announcements do not establish human efficacy or results for the proposed combination with NBIP-‘2118.
Neurocrine Biosciences has announced the initiation of a Phase 1 clinical study evaluating NBIP-‘1968, an investigational long-acting peptide targeting three of the most closely watched metabolic receptors in obesity research:
GLP-1.
GIP.
Glucagon.
If that combination sounds familiar, it should.
It is the same general three-receptor architecture that made Retatrutide one of the most closely followed investigational metabolic compounds in the world.
But NBIP-‘1968 should not simply be described as “another Retatrutide.”
The details are considerably more interesting. For a separate evidence-based comparison of the two candidates, see Eloralintide Research’s NBIP-1968 overview. Shared receptor targets do not establish comparable clinical outcomes.
Neurocrine describes its proprietary molecule as a GIP/GLP-1-preferring triple agonist with relatively lighter glucagon activity.
November 2, 2026 status: Neurocrine’s third-quarter 2026 earnings release filed with the SEC continued to describe the initiated Phase 1 trial for NBIP-‘1968 and a separate Phase 1 program for NBIP-‘2118. The company says findings from both programs will inform the proposed co-formulated combination; it did not report human efficacy results for the combination. Neurocrine’s original announcement styles the code NBIP-‘1968 (sometimes written without the apostrophe as NBIP-1968). Its clinical-studies listing uses NBIP-01968 for the triple agonist and NBIP-02118 for the separate CRF2 agonist; the listing describes studies, not combination results.
That raises a fascinating question:
What happens when researchers keep the same three metabolic targets but deliberately change the balance between them?
Why the balance matters: Two compounds can target the same three receptors yet differ in how strongly they activate each pathway, how long they remain active and how they perform in a trial. Neurocrine’s description is a design claim; the Phase 1 study must establish its own human safety and pharmacology before any clinical ranking against retatrutide is possible.
| Question | NBIP-1968 | Retatrutide |
|---|---|---|
| Targets | GLP-1, GIP and glucagon | GLP-1, GIP and glucagon |
| Research discussed here | Phase 1 study announced | Phase 3 research |
| Direct comparison | No established head-to-head winner | No established head-to-head winner |
What Is NBIP-‘1968?
NBIP-‘1968 is an investigational peptide developed by Neurocrine Biosciences for obesity and metabolic disease research.
It is designed to activate three receptors:
- GLP-1 receptor
- GIP receptor
- Glucagon receptor
This makes it a triple receptor agonist.
Neurocrine has designed the molecule as a long-acting peptide intended for once-weekly subcutaneous administration.
Research status, checked November 4, 2026: Neurocrine’s Phase 1 announcement describes a first-in-human study of NBIP-‘1968. In its November 2, 2026 quarterly update, the company reiterated the study’s initiation. These announcements do not report efficacy results, and the compound remains investigational.
According to Neurocrine’s Phase 1 announcement, the initial portion evaluates the safety and tolerability of single ascending doses in adults across a range of body mass index categories. The company’s announcement is a study description, not a report of clinical results. Early-development questions can include:
- Safety
- Tolerability
- Pharmacokinetics
- Pharmacodynamics
- Exposure across escalating doses
That distinction is important.
There are not yet Phase 2 or Phase 3 human weight-loss results for NBIP-‘1968.
Any claim that NBIP-‘1968 is already “better than Retatrutide” would therefore be wildly premature.
What makes the molecule interesting today isn’t proven superiority.
It’s the pharmacological strategy behind it.
Why Target GLP-1, GIP and Glucagon Together?
The evolution of modern metabolic drugs increasingly resembles researchers assembling different pieces of the body’s energy-regulation system.
Each receptor contributes something different.
GLP-1
GLP-1 receptor activation has become one of the foundations of modern obesity and diabetes pharmacology.
GLP-1 signaling can influence:
- Appetite
- Satiety
- Food intake
- Insulin secretion
- Glucose regulation
- Gastric emptying
Semaglutide demonstrated how powerful targeting this pathway could become.
But researchers didn’t stop there.
GIP
GIP is another incretin hormone involved in metabolic signaling and insulin secretion.
Combining GIP receptor activity with GLP-1 receptor activity became a major milestone with Tirzepatide.
Instead of relying on a single hormonal pathway, researchers could influence two complementary incretin systems simultaneously.
That opened the door to an even bigger question.
What if researchers added a third receptor?
Enter the Glucagon Receptor
Glucagon may be the most intriguing part of the triple-agonist concept.
While GLP-1 and GIP are strongly associated with incretin biology, glucagon signaling influences several additional metabolic processes, including hepatic glucose regulation and energy expenditure.
The challenge is balance.
Too little glucagon receptor activity may limit its potential metabolic contribution.
Too much could potentially create unwanted effects.
The objective therefore isn’t simply:
Activate glucagon.
It is:
Determine the receptor balance that produces the most favorable overall metabolic profile.
And this is precisely where NBIP-‘1968 becomes interesting.
NBIP-‘1968 vs Retatrutide: Same Receptors, Different Molecules
Retatrutide and NBIP-‘1968 share the same broad receptor targets.
But that does NOT make them pharmacologically identical.
| Compound | GLP-1 | GIP | Glucagon | Development |
|---|---|---|---|---|
| Semaglutide | ✓ | — | — | Approved GLP-1 therapy |
| Tirzepatide | ✓ | ✓ | — | Approved dual agonist |
| Retatrutide | ✓ | ✓ | ✓ | Investigational triple agonist |
| NBIP-‘1968 | ✓ | ✓ | ✓ | Investigational Phase 1 program |
The crucial distinction may eventually be relative receptor activity.
Neurocrine has described its proprietary triple agonist as GIP/GLP-1-preferring and “light” on glucagon activity.
That wording matters.
Neurocrine describes the profile qualitatively as preferring GIP and GLP-1 activity with lighter glucagon activity. The company description does not supply a numerical receptor-activity ratio for this article.
GLP-1 receptor: part of the reported target profile.
GIP receptor: part of the reported target profile.
Glucagon receptor: described by the company as lighter in activity.
Another triple agonist may have a different receptor activity profile. A meaningful quantitative comparison requires comparable assay data.
Both compounds would technically be GLP-1/GIP/glucagon triple agonists.
Their biological effects could nevertheless differ substantially.
This is why counting receptors alone tells only part of the story.
The Triple-Agonist Race May Become a Receptor-Ratio Race
For several years, obesity-drug development could almost be summarized by receptor count:
One receptor.
Then two.
Then three.
But the next phase is likely to become much more sophisticated.
Researchers are increasingly interested in questions such as:
How strongly should each receptor be activated?
How long should that activation persist?
Can efficacy be maintained while improving tolerability?
Does changing receptor balance alter fat loss, lean mass, glucose control or energy expenditure?
Two compounds targeting identical receptors may produce different outcomes if their receptor potency, molecular structure, pharmacokinetics or exposure profiles differ.
That means the future competition may not simply be:
Single agonist vs dual agonist vs triple agonist.
It may become:
Triple agonist vs better-designed triple agonist.
But NBIP-‘1968 Is Only Half of Neurocrine’s Obesity Strategy
This is where the Neurocrine program gets considerably more interesting.
The company is simultaneously developing another investigational peptide:
NBIP-‘2118
NBIP-‘2118 is a selective corticotropin-releasing factor type 2 receptor agonist, generally abbreviated CRF2 agonist.
And unlike another incretin drug, NBIP-‘2118 is being investigated through a completely different biological pathway.
Neurocrine’s research is exploring whether CRF2 activation could contribute to weight reduction while helping preserve lean mass.
Why does that matter?
Because one of the increasingly important questions surrounding major pharmacological weight loss isn’t merely:
How much weight disappeared?
Researchers also want to know:
What kind of weight disappeared?
The Next Obesity Battleground: Fat Loss vs Lean Mass
Large reductions in body weight can include reductions in both fat mass and lean tissue.
That has pushed body composition into the center of next-generation obesity research.
The ideal future therapy wouldn’t merely produce a smaller number on a scale.
Researchers increasingly want therapies capable of producing:
Substantial fat reduction
while maintaining as much:
Lean tissue
as possible.
Neurocrine believes CRF2 biology may offer one possible strategy for addressing that challenge.
Its preclinical research has explored NBIP-‘2118 both independently and alongside its proprietary triple agonist.
And that leads to the company’s larger strategy.
Triple Agonist + CRF2: Neurocrine’s Bigger Experiment
Neurocrine has outlined a development strategy involving its own triple agonist, NBIP-‘1968, together with NBIP-‘2118. For background on a different triple agonist, see our retatrutide molecular-identity discussion. Retatrutide is not Neurocrine’s compound.
Conceptually:
GLP-1 + GIP + Glucagon
combined with
CRF2 receptor agonism
The objective isn’t simply maximum weight reduction.
The company is investigating whether the combination can optimize several variables simultaneously:
- Total weight reduction
- Fat-mass reduction
- Lean-mass preservation
- Metabolic effects
- Tolerability
That represents a larger change occurring throughout metabolic drug development.
The industry is beginning to move beyond asking:
“How much weight can this drug make someone lose?”
The better question is becoming:
“What is the quality of that weight loss?”
Neurocrine Is Exploring Multiple Ways to Combine These Pathways
The company’s research presentations reveal another fascinating element of the program.
Neurocrine has explored different approaches for combining incretin and CRF2 biology.
Co-formulation
Two compounds can potentially be combined while allowing researchers to adjust the ratio between them.
That flexibility could theoretically allow investigators to tune the balance between efficacy, tolerability and body-composition effects.
Single-Molecule Conjugates
Neurocrine has also explored attaching incretin and CRF2 pharmacology within a single molecular construct.
That approach could potentially simplify future development, although molecular design becomes substantially more complicated.
The important point isn’t which approach ultimately wins.
It’s what Neurocrine is trying to optimize.
This isn’t simply another race toward the largest weight-loss percentage.
It’s an attempt to engineer the composition and quality of weight reduction.
Retatrutide vs NBIP-‘1968 vs Eloralintide: Three Different Strategies
This becomes especially interesting when we zoom out.
Several major metabolic research programs are attacking obesity through fundamentally different combinations of hormonal pathways.
| Compound | Primary Mechanism | Research Strategy |
| Semaglutide | GLP-1 | Single incretin pathway |
| Tirzepatide | GLP-1 + GIP | Dual incretin |
| Retatrutide | GLP-1 + GIP + glucagon | Triple agonism |
| NBIP-‘1968 | GLP-1 + GIP + glucagon | GIP/GLP-1-preferring triple agonism |
| Eloralintide | Amylin receptor agonism | Alternative satiety pathway |
| NBIP-‘2118 | CRF2 agonism | Body composition / metabolic pathway |
And this is where the future gets much bigger than GLP-1.
The Future May Be About Combining Different Biological Systems
For years, researchers largely concentrated on making incretin drugs increasingly powerful.
GLP-1.
Then GLP-1 + GIP.
Then GLP-1 + GIP + glucagon.
But another trend is emerging.
Instead of simply adding another incretin-related receptor, researchers are beginning to combine entirely different biological systems.
We’ve already seen enormous interest surrounding Eloralintide, Lilly’s investigational selective amylin receptor agonist.
Eloralintide doesn’t simply attempt to become another GLP-1.
It targets amylin biology.
Researchers are now studying Eloralintide both independently and alongside Tirzepatide.
Neurocrine appears to be pursuing a conceptually similar next-generation philosophy from another direction:
Incretin biology + CRF2 biology.
Different companies.
Different pathways.
Similar larger idea.
The future of obesity pharmacology may belong not to one magical receptor, but to intelligently combining complementary biological systems.
Why NBIP-‘1968 Matters Even Though It’s Only Phase 1
It would be easy to dismiss NBIP-‘1968 because Retatrutide is dramatically further along in development.
That misses the bigger story.
The importance of NBIP-‘1968 today isn’t that it has demonstrated better clinical results.
It hasn’t.
The importance is that another major biotechnology company has independently chosen GLP-1/GIP/glucagon triple agonism as the foundation of an obesity-development program.
That provides another signal that triple-receptor pharmacology isn’t simply one experimental curiosity.
It has become a legitimate development strategy.
And Neurocrine is already looking beyond the triple agonist itself.
The company is asking what happens when that foundation is combined with another pathway intended to influence body composition.
That’s where this program becomes worth watching.
What Researchers Need to See Next
NBIP-'1968 remains an early-stage investigational program. For the sponsor's latest development information, consult the Neurocrine pipeline. Shared receptor targets do not establish equivalent clinical effects across different compounds.
What would make the comparison meaningful? Evidence of receptor activity in an early study does not establish weight-loss efficacy, long-term tolerability, or superiority over another triple agonist. The informative next steps are published exposure data, dose-response findings, controlled clinical outcomes and clear adverse-event reporting. Compare the evidence stage with our UBT251 Phase 2 review, while keeping the compounds and study populations separate.
The most important information will come from human clinical research.
Researchers will want answers to several questions.
Is NBIP-‘1968 well tolerated?
Triple agonism can look spectacular in preclinical models.
Humans have an irritating habit of being more complicated.
Safety and tolerability therefore come first.
What does its pharmacokinetic profile look like?
A successful weekly metabolic therapy requires sustained and predictable exposure.
How much glucagon receptor activity is optimal?
Neurocrine’s deliberately lighter glucagon profile makes this particularly interesting.
What happens to body composition?
Eventually, researchers will want to distinguish total weight reduction from fat and lean-mass changes.
Does combining the triple agonist with NBIP-‘2118 improve the outcome?
This may ultimately be the biggest question surrounding Neurocrine’s entire metabolic program.
The Bigger Picture: Obesity Drugs Are Becoming Metabolic Platforms
Semaglutide proved that GLP-1 pharmacology could fundamentally reshape obesity treatment.
Tirzepatide demonstrated the potential of dual agonism.
Retatrutide pushed the field toward triple agonism.
Eloralintide has helped bring amylin biology into the next major wave of research.
NBIP-‘1968 and NBIP-‘2118 now provide another glimpse of where the field may be heading.
The next generation may not be defined by one receptor or even one molecule.
Instead, researchers may increasingly construct metabolic platforms designed to influence multiple complementary systems:
Appetite.
Satiety.
Glucose regulation.
Energy expenditure.
Fat mass.
Lean mass.
Long-term tolerability.
That is a far more ambitious objective than simply suppressing appetite.
And we’re probably still near the beginning.
Frequently Asked Questions About NBIP-‘1968
What is NBIP-‘1968?
NBIP-‘1968 is an investigational long-acting peptide from Neurocrine Biosciences being studied for obesity. It targets GLP-1, GIP and glucagon receptors and has entered early Phase 1 clinical development.
Is NBIP-‘1968 a GLP-1 drug?
Partly, but describing it simply as a GLP-1 drug is incomplete. NBIP-‘1968 is designed as a triple agonist targeting GLP-1, GIP and glucagon receptors.
Is NBIP-‘1968 the same as Retatrutide?
No. Both target GLP-1, GIP and glucagon receptors, but they are different investigational molecules. Relative receptor activity, molecular design, pharmacokinetics and clinical profiles may differ substantially.
What makes NBIP-‘1968 different from Retatrutide?
One particularly interesting distinction is Neurocrine’s description of its proprietary triple agonist as GIP/GLP-1-preferring with comparatively lighter glucagon activity. Whether that ultimately creates meaningful clinical differences remains unknown.
What is NBIP-‘2118?
NBIP-‘2118 is Neurocrine’s investigational selective CRF2 receptor agonist being studied for obesity and metabolic disease. Neurocrine is exploring CRF2 activation as a potential approach to weight reduction with greater preservation of lean tissue.
Why would Neurocrine combine NBIP-‘1968 with NBIP-‘2118?
The research strategy is designed to investigate whether combining incretin/triple-agonist pharmacology with CRF2 activation could improve total weight reduction and body composition while maintaining acceptable tolerability.
Is NBIP-‘1968 approved by the FDA?
No. NBIP-‘1968 is investigational and remains in early clinical development. It has not been approved as a treatment for obesity or any other condition.
Are there human weight-loss results for NBIP-‘1968?
No human weight-loss results were reported in the company announcements reviewed through November 2, 2026. Early Phase 1 research focuses on safety, tolerability and pharmacological characteristics; meaningful efficacy comparisons with established or later-stage therapies would be premature.
Final Thoughts
NBIP-‘1968 isn’t important because researchers have already proven it can outperform Retatrutide.
They haven’t.
It’s important because it illustrates where metabolic research is going next.
The first generation demonstrated the power of GLP-1.
The next added GIP.
Then came glucagon.
Now researchers are adjusting the balance among those receptors while simultaneously exploring completely different biological systems such as amylin and CRF2.
The question is no longer simply:
How many receptors can one drug activate?
The much more interesting question is:
Which combination of pathways produces the best metabolic outcome with the best tolerability and the best body composition?
NBIP-‘1968 gives researchers another experiment designed to help answer that question.
And if the history of metabolic research over the last several years tells us anything, the receptor arms race probably isn’t finished yet.
Research Disclaimer
NBIP-‘1968, NBIP-‘2118, Retatrutide and Eloralintide are discussed here in the context of scientific and clinical research. Investigational compounds have not necessarily been approved by the U.S. Food and Drug Administration for treatment or general clinical use. This article is educational and is not medical advice.